Xuanjie Pharmaceutical

Meridigen Biotech, also known as Xuanjie Pharmaceutical, is a clinical-stage biotechnology company headquartered in Taiwan that specializes in the development of mesenchymal stem cell (MSC) therapies. The company leverages its proprietary platform to derive high-quality stem cells from human umbilical cord tissue, focusing on neonatal diseases and inflammatory respiratory conditions. Its lead candidate, UMC101, is currently being evaluated in Phase 2 clinical trials for the treatment of bronchopulmonary dysplasia and is also in development for hypoxic-ischemic encephalopathy. Meridigen operates integrated facilities for cell processing and storage that comply with international GMP standards. The company aims to address significant unmet medical needs in pediatrics and regenerative medicine through its advanced cell therapy pipeline.